BELLE-2: Fulvestrant ± Buparlisib in HR+/HER2- Advanced Breast Cancer

Slideset - The combination of the investigational PI3K inhibitor buparlisib with fulvestrant extended PFS in patients with HR+/HER2- advanced breast cancer who progressed on previous AI therapy.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research